[CELG] Celgene Corporation

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 78.56 B

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 118.93 Change: 1.06 (0.9%)
Ext. hours: Change: 0 (0%)

chart CELG

Refresh chart

Strongest Trends Summary For CELG

CELG is in the medium-term up 27% in 7 months. In the long-term up 998% in 26 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. The company?s commercial stage products include REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML); ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; and POMALYST/IMNOVID for the treatment of multiple myeloma. Its commercial stage products also comprise THALOMID for the patients with multiple myeloma and for the acute treatment of the cutaneous manifestations of erythema nodosum leprosum; ISTODAX to treat cutaneous T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN LA products. The company?s

Fundamental Ratios
Shares Outstanding774.6 M EPS3.09 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 14.91% Sales Growth - Q/Q9.47% P/E39.6
P/E To EPS Growth P/S9.32 P/BV12.43 Price/Cash Per Share10.49
Price/Free Cash Flow29.58 ROA12.38% ROE34.76% ROI15.22%
Current Ratio3.34 Quick Ratio3.2 Long Term Debt/Equity0.9 Debt Ratio0.47
Gross Margin95.19% Operating Margin31.72% Net Profit Margin26.08% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-951.3 M Cash From Investing Activities239.7 M Cash From Operating Activities1.14 B Gross Profit2.18 B
Net Profit356.2 M Operating Profit412.4 M Total Assets17.75 B Total Current Assets9.88 B
Total Current Liabilities2.96 B Total Debt7.62 B Total Liabilities11.42 B Total Revenue2.28 B
Technical Data
High 52 week96.88 Low 52 week59.21 Last close95.42 Last change-0.09%
RSI55.66 Average true range1.1 Beta1.07 Volume2.51 M
Simple moving average 20 days0.58% Simple moving average 50 days3.1% Simple moving average 200 days12.36%
Performance Data
Performance Week-0.09% Performance Month1.19% Performance Quart5.22% Performance Half35.85%
Performance Year17.28% Performance Year-to-date48.88% Volatility daily0.69% Volatility weekly1.54%
Volatility monthly3.16% Volatility yearly10.94% Relative Volume218.43% Average Volume8.89 M
New High New Low

News

2019-06-26 17:40:00 | The 2 Biggest Casualties From the Celgene-Bristol-Myers Merger So Far

2019-06-26 11:00:29 | Big Pharma Has to Bet Big on M&A. Investors Don’t.

2019-06-26 11:00:03 | AbbVie to Buy Allergan: Prescribed ETFs

2019-06-26 09:26:01 | AbbVie to Acquire Allergan in Nearly $62B Cash & Stock Deal

2019-06-26 09:22:01 | The Zacks Analyst Blog Highlights: AbbVie, Allergan, Bristol-Myers and Celgene

2019-06-25 16:15:08 | AbbVie + Allergan: Where Are The Synergies?

2019-06-25 15:56:07 | Bristol-Myers to Sell Otezla for Celgene Merger, Shares Down

2019-06-25 11:02:00 | The 10 Biggest Biotech Stocks

2019-06-25 10:11:02 | AbbVie Announces Lifting of FDA's Partial Hold on CANOVA Study

2019-06-25 09:35:01 | Company News For Jun 25, 2019

2019-06-24 20:06:30 | Traders Still Avoiding Small Caps

2019-06-24 16:55:57 | What Happened in the Stock Market Today

2019-06-24 16:29:19 | US STOCKS-S&P 500 slips as healthcare drags, investors eye G20 summit

2019-06-24 16:26:00 | Stocks End Mixed as Wall Street Looks to G-20 Summit for U.S.-China Trade Talks

2019-06-24 16:23:08 | Why These Innovative Biotech ETFs Soaring

2019-06-24 16:14:08 | Celgene Told To Divest Blockbuster Drug — And Other Bad News For Bristol

2019-06-24 15:51:06 | Bristol-Myers Squibb Company -- Moody's: Bristol's Otezla divestiture credit negative

2019-06-24 15:47:34 | 5 Top Stock Trades for Tuesday: CELG, BMY, CZR

2019-06-24 15:17:23 | Bristol-Myers tumbles as its $74 billion merger with Celgene faces setback

2019-06-24 14:27:39 | US STOCKS-Wall Street struggles for direction ahead of G20 summit

2019-06-24 13:14:48 | Bristol-Myers Slips As Regulatory Hiccups Delay Celgene Deal; Liver Cancer Study Faces Setback

2019-06-24 13:12:37 | US STOCKS-Wall St flat as healthcare losses limit tech gains

2019-06-24 12:03:18 | Bristol-Myers Will Divest Celgene Blockbuster to Close Deal

2019-06-24 11:29:40 | US STOCKS-Wall St edges higher as tech gains more than offset healthcare losses

2019-06-24 10:56:08 | Bristol-Myers plans to divest Celgene's psoriasis drug

2019-06-24 10:52:00 | Bristol-Myers Plans Otezla Sale to Win FTC Approval for $74 Billion Celgene Deal

2019-06-24 10:39:18 | US STOCKS-Wall Street edges higher as tech offsets healthcare loss

2019-06-24 10:04:58 | To allay FTC concerns, Bristol-Myers to sell Celgene psoriasis treatment

2019-06-24 09:00:00 | Bristol-Myers Squibb Stock Is Falling as Celgene Deal Is Delayed

2019-06-24 08:14:00 | UPDATE: Bristol-Myers offers update on liver cancer trial, to sell Otezla to hasten close of Celgene deal

2019-06-21 10:01:02 | 3 Big Biotechs Hold Growth Potential in Second Half of 2019

2019-06-21 09:15:01 | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF PBE?

2019-06-21 08:53:12 | 5 Best-Performing S&P 500 Stocks So Far This Year

2019-06-21 08:00:00 | Where Will bluebird bio Be in 1 Year?

2019-06-20 17:00:00 | 3 Drugs Under FDA Review With Blockbuster Potential

2019-06-20 09:05:00 | What Should Celgene's Investors Do With Everything Bristol-Meyer Squibb Is Giving Them?

2019-06-19 17:45:00 | This would be the worst-case scenario for health companies, according to UBS

2019-06-19 16:07:08 | Alexion's ALXN Ultomiris Gets Approval in Japan for PNH

2019-06-19 12:02:04 | Zacks.com featured highlights include: Citigroup, DSW, Celgene and Zions

2019-06-19 09:06:01 | Big Drugmakers That May Tread the M&A Path After Pfizer

2019-06-18 09:25:01 | Celgene CELG Hits 52-Week High, Can the Run Continue?

2019-06-18 08:55:12 | 4 High Earnings Yield Stocks to Strengthen Your Portfolio

2019-06-18 08:05:44 | See what the IHS Markit Score report has to say about Celgene Corp.

2019-06-18 07:31:03 | The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale

2019-06-17 15:41:07 | Novartis NVS Announces Promising Data on Tasigna & Hyrimoz

2019-06-17 09:12:01 | Regeneron REGN Presents Positive Data on Lymphoma Candidate

2019-06-16 09:00:00 | Is It Too Late to Buy Celgene Stock?

2019-06-14 09:00:00 | Leoplus USA Wins Lyfebulb-Celgene 2019 _Addressing Unmet Needs in MS: An Innovation Challenge_

2019-06-14 08:47:08 | The Daily Biotech Pulse: Hematology And Rheumatology Conference Presentations Take The Spotlight, Eton In-Licenses Epilepsy Drug NDA

2019-06-14 08:29:12 | Mallinckrodt Presents Encouraging Data on Acthar Gel for RA